NCT02550145

Role of GLP-1 in Hyperinsulinemic Hypoglycemia Post-bariatric Surgery

The Role of GLP-1 in Mediating Glucose Reductions After Bariatric Surgery

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: Tracey McLaughlin · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the role of GLP-1 in causing extreme postprandial glucose reductions after bariatric surgery in a subset of patients who have severe symptomatic hypoglycemia.

Detailed description

The physiologic mechanisms mediating the glucose-lowering effect of Roux-en-Y Gastric Bypass (RYGB) or post-Vertical Sleeve Gastrectomy (VSG) are unknown. The reduction in glucose excursions prior to weight loss has lead to postulates that the incretin hormone, GLP-1, may play an important role. The purpose of this study is to evaluate the role of GLP-1 in causing extreme postprandial glucose reductions in a subset of post-bariatric patients through the pharmacologic blockade of the GLP-1 receptor in post-RYGB or post-VSG patients with severe symptomatic hypoglycemia.

Conditions

• Hypoglycemia

Interventions

Type	Name	Description
DRUG	Exendin (9-39)	IV infusion of Exendin (9-39) during standardized oral glucose tolerance test (OGTT).
OTHER	Placebo	IV infusion of Placebo (normal saline) during standardized oral glucose tolerance test (OGTT)

Timeline

• Start date: 2014-02-01
• Primary completion: 2016-12-01
• First posted: 2015-09-15
• Last updated: 2024-12-04

Locations

1 site across 1 country: United States